In This Section      

Ciccarone Articles

Ciccarone Center Research


Cholesterol / Lipids / Statins

Landmark Articles

Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
By: Subedi BH, Joshi PH, Jones SR, Martin SS, Blaha MJ, Michos ED.
This review outlined current therapies and described future directions for potential new approaches for HDL therapeutics, including HDL infusions, delipidated HDL, liver X receptor agonists, Apo A-I upregulators, Apo A mimetics, and gene therapy.
Read on Pubmed
Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines.
By: Martin SS, Blumenthal RS.
This editorial discusses the strengths and limitations of the new prevention guidelines.
Read on Pubmed
Cardiometabolic risk is associated with atherosclerotic burden and prognosis: results from the partners coronary computed tomography angiography registry.
By: Hulten E, Bittencourt MS, O’Leary D, Shah R, Ghoshhajra B, Christman MP, Montana P, Steigner M, Truong QA, Nasir K, Rybicki F, Hainer J, Brady TJ, Di Carli MF, Hoffmann U, Abbara S, Blankstein R.
Patients without diabetes who have multiple metabolic risk factors have a similar prognosis and burden of CAD as those with Type 2 diabetes not requiring insulin.
Read on Pubmed
Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol.
By: Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang ZZ, Bizon C, Lange EM, Smith JD... Turner O‘Donnell CJ, Post WS, et al.
This large, whole-exome-sequencing study for LDL-C identified a gene not known to be implicated in LDL-C and provides unique insight into the design and analysis of similar experiments.
Read on Pubmed
Are we moving towards concordance on the principle that lipid discordance matters?
By: Martin SS, Michos ED.

The paper addresses the underappreciated concept of discordance between different lipid and lipoprotein measures in individual patients. The investigators address the prevalence of such discordance and its association with long-term incidence of coronary events.

Read on Pubmed
Polypill therapy, subclinical atherosclerosis, and cardiovascular events — implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis).
By: Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, Agatston AS, Nasir K.
The authors conclude that avoidance of polypill therapy in individuals with subclinical atherosclerosis could allow for a more selective use of the treatment and, as a result, avoidance of treatment in those who are unlikely to benefit.
Read on Pubmed
Genetics and personalized medicine — a role in statin therapy?
By: Patel J, Abd T, Blumenthal RS, Nasir K, Superko HR.

The primary goal of this study was to feature the most important genes involved in lipid metabolism, clinical outcomes, and statin-induced side effects, highlighting genomewide association studies and the candidate gene approach.The primary goal of this study was to feature the most important genes involved in lipid metabolism, clinical outcomes, and statin-induced side effects, highlighting genome-wide association studies and the candidate gene approach.

Read on Pubmed
Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.
By: Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K.
CAC scoring can help match statin therapy to absolute atherosclerotic CVD risk.
Read on Pubmed
Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease.
By: Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, Blumenthal RS, Meneghelo RS, Conceiçao RD, Santos RD, Nasir K.
These results favor statin use in subjects with nonalcoholic fatty liver disease, since its use is not associated with the presence of the disease or increased fibrosis.
Read on Pubmed
The risk discussion: A key virtue of the 2013 ACC/AHA cholesterol treatment guidelines.
By: Martin SS, Stone NJ, Blumenthal RS.